Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.62 |
| ▸ | KIF11 | P52732 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13210392 | 0.91 | HSD11B1 (0.59) | HSD11B1ARMAOAMAOBPDK1 | |
| SCHEMBL13265385 | 0.80 | HSD11B1 (0.48) | HSD11B1ARPDK1PDK2PDK3 | |
| SCHEMBL2902016 | 0.76 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL13239492 | 0.76 | HPGD (0.44) | HSD11B1ARMAOAMAOB | |
| SCHEMBL13239483 | 0.76 | MAOA (0.54) | ARMAOAMAOB | |
| SCHEMBL2324355 | 0.75 | HSD11B1 (0.57) | HSD11B1KIF11ARPTPN5 | |
| SCHEMBL13239440 | 0.68 | HSD11B1 (0.78) | HSD11B1 | |
| SCHEMBL14378078 | 0.68 | AR (0.61) | ARMAOAMAOB | |
| SCHEMBL5712493 | 0.67 | HSD11B1 (0.76) | HSD11B1 | |
| SCHEMBL2908187 | 0.66 | HSD11B1 (1.00) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754890-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754890-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | AMGEN INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | AMGEN INC. | 2008-10-30 | — | — | US | disclosed |
| US-7402704-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402704-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2008-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | ARSA, SULT2A1, UGT2B7 | HSD11B1 108/4885KIF11 4355/4885AR 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.